Cellnovo to Market its Diabetes Management System in Italy

PARIS--()--Regulatory News:

Cellnovo Group (Paris:CLNV) (“Cellnovo” CLNV:EN Paris), a medical technology company marketing the first connected all-in-one diabetes management system, today announces it has completed the full registration process required by the Italian Ministry of Health for medical devices and is now able to import and distribute the Cellnovo diabetes management system in Italy.

There are estimated to be more than 300,000 Type 1 diabetes patients in Italy.1 The launch in this market marks an important further step in Cellnovo’s European commercialisation strategy. The launch also follows the recent announcement of first sales in The Netherlands and increasing sales in France and the UK.

In support of successful commercialisation in Italy and continuing to raise the profile of Cellnovo’s technology internationally, the Company was also present at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Milan from 3rd to 6th February. ATTD is the biggest European meeting covering technology for diabetes and brings together clinicians and thought leaders from more than 90 countries.

Sophie Baratte, CEO of Cellnovo, commented: “We are pleased to see the Italian market open for our unique diabetes management system. This is another key milestone in building out our commercial platform ahead of our anticipated scale up in manufacturing capacity in H2 2016 as Flex (Flextronics) comes fully on line.

“During ATTD, we saw a lot of traction on our booth with many clinicians, among them Italians, expressing interest in the wearability of our innovative patch pump and the potential the Cellnovo system offers by its e-connectivity. We look forward to making our technology available to Italian patients.”

1Association of Diabetes in Italy (http://www.aemmedi.it/)

------

About Cellnovo (Euronext: CLNV)
An international commercial medical technology company, Cellnovo markets the first mobile, connected all-in-one diabetes management system, a disruptive technology enhancing daily disease management for Type 1 diabetes patients. Cellnovo’s device currently addresses the $2.2 billion insulin pump market and the Company is reviewing the potential for the device to serve other markets. Cellnovo is currently marketing the device in the UK, France and The Netherlands and has a clearly defined commercial and manufacturing strategy supported by strategic partners Air Liquide and Flextronics. Cellnovo is headquartered in Paris France with product development facilities in Wales, UK. For further information please visit www.cellnovo.com

About the Cellnovo Diabetes Management System
Compact, tubeless, intuitive and entirely connected, Cellnovo’s insulin pump comprises a mobile touchscreen controller with an integrated blood-glucose meter. This unique device allows optimal management of insulin injections with drop-by-drop precision, whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient’s condition to be continually monitored by family members and healthcare professionals in real-time.

Cellnovo is listed on Euronext, Compartment C

ISIN: FR0012633360 – Ticker: CLNV

Contacts

Cellnovo
Chief Executive Officer
Sophie Baratte
investors@cellnovo.com
or
NewCap
Investor Relations
Emmanuel Huynh, + 33 1 44 71 00 16
Media Relations in France
Nicolas Merigeau, + 33 1 44 71 94 98
cellnovo@newcap.eu
or
Consilium Strategic Communications
Media Relations in United Kingdom
Amber Fennell, Chris Gardner, Chris Welsh, Laura Thornton, +44 20 3709 5700
cellnovo@consilium.com

Contacts

Cellnovo
Chief Executive Officer
Sophie Baratte
investors@cellnovo.com
or
NewCap
Investor Relations
Emmanuel Huynh, + 33 1 44 71 00 16
Media Relations in France
Nicolas Merigeau, + 33 1 44 71 94 98
cellnovo@newcap.eu
or
Consilium Strategic Communications
Media Relations in United Kingdom
Amber Fennell, Chris Gardner, Chris Welsh, Laura Thornton, +44 20 3709 5700
cellnovo@consilium.com